Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:44 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
NCT04478994 · Amgen · PHASE1 · terminated · last registry update 2024-06-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Poor enrollment” | – | Registry record, Amgen |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IGF1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-11-20Also stopped (terminated): Astellas Pharma Inc, OSI-906 + Placebo (NCT01101906)
- 2024-11-08Results posted on the registry: NantBioScience, Inc., Gemcitabine + AMG 479 (NCT01318642)
- 2024-11-08Also stopped (terminated): NantBioScience, Inc., Gemcitabine + AMG 479 (NCT01318642)
- 2024-10-17Results posted on the registry: NantCell, Inc., AMG 479 + AMG 655 (NCT00630552)
- 2024-09-25Results posted on the registry: NantCell, Inc., AMG 479 + AMG 479 (NCT00807612)
- 2024-09-25Also stopped (terminated): NantCell, Inc., AMG 479 + AMG 479 (NCT00807612)
- 2024-09-19Results posted on the registry: NantCell, Inc., AMG 479 + Placebo (NCT00626106)
- 2024-08-23Results posted on the registry: NantCell, Inc., AMG 479 + Etoposide (NCT00791154)
- 2024-08-23Also stopped (terminated): NantCell, Inc., AMG 479 + Etoposide (NCT00791154)
- 2024-08-20Results posted on the registry: NantCell, Inc., AMG 479 + AMG 655 (NCT00819169)
- 2024-08-20Also stopped (terminated): NantCell, Inc., AMG 479 + AMG 655 (NCT00819169)
- 2024-08-01Also stopped (terminated): Dana-Farber Cancer Institute, Palbociclib + Ganitumab (NCT04129151)
- 2024-07-17Results posted on the registry: Dana-Farber Cancer Institute, Palbociclib + Ganitumab (NCT04129151)
- 2024-07-16Results posted on the registry: NantCell, Inc., AMG 479 + Placebo (NCT01231347)
- 2024-04-26Results posted on the registry: Amgen, TEPEZZA + Placebo (NCT04583735)
- 2024-04-25Phase 3 first posted: Viridian Therapeutics, Inc., Veligrotug (NCT06384547)
- 2024-02-28Results posted on the registry: Children's Hospital Medical Center, Cincinnati, Increlex (NCT02636270)
- 2024-02-08Phase 3 first posted: Amgen, Teprotumumab (NCT06248619)
- 2024-02-08Results posted on the registry: Icahn School of Medicine at Mount Sinai, IGF-1 + Placebo/saline (NCT01970345)
- 2024-02-08Also stopped (terminated): Icahn School of Medicine at Mount Sinai, IGF-1 + Placebo/saline (NCT01970345)
- 2023-12-22Phase 3 first posted: Viridian Therapeutics, Inc., Veligrotug (NCT06179875)
- 2023-11-01Phase 3 first posted: Sling Therapeutics, Inc., linsitinib (NCT06112340)
- 2023-09-01Phase 3 first posted: Viridian Therapeutics, Inc., Veligrotug + Placebo (NCT06021054)
- 2023-07-06Results posted on the registry: Ipsen, mecasermin (NCT00571727)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision